Kunal Mahajan: Lipoprotein(a) and LDL-C Target Attainment in ACS Patients
Kunal Mahajan, Director and Chief Interventional Cardiologist at Himachal Heart Institute, shared a post on X about a recent article he and his colleagues co-authored, adding:
“Happy to share our study in the Journal of Clinical Lipidology.
In ACS patients treated with triple oral lipid-lowering therapy, lipoprotein(a) increased significantly after ACS, and higher baseline lipoprotein(a) predicted failure to achieve low-density lipoprotein cholesterol less than fifty milligrams per deciliter at one month.”
Title: Changes in Lipoprotein(a) and Their Association With LDL-C in ACS Patients Treated with Triple Oral Lipid-Lowering Therapy
Authors: Kunal Mahajan, Nitin Mahajan, Jai Bharat Sharma, Surender Himral, Tanuj Bhatia, Deep Dutta
Read the Full Article on Journal of Clinical Lipidology
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 14, 2026, 13:43Edward Lee Carter: Optimizing Anticoagulation in Cirrhosis Beyond the Lab Numbers
-
Aug 14, 2026, 13:39Amr Saad: What Tips You Toward Cerebral Venous Thrombosis Over IIH?
-
Aug 14, 2026, 13:28Eduardo Medronha: DIPS as a Rescue Strategy in Budd–Chiari Syndrome
-
Aug 14, 2026, 13:18Immune Checkpoint Inhibitors Have Transformed Cancer Treatment – RPTH Journal
-
Aug 14, 2026, 13:04Mohammed M. Aboudeif: Cerebral Venous Thrombosis – Think Early, Treat Decisively
-
Aug 14, 2026, 12:49Ahmed Hawash: The Hawash Method for Managing Extreme ICU Complexity
-
Aug 14, 2026, 12:42Why Unfractionated Heparin Still Matters in Modern Anticoagulation – Thrombosis Canada
-
Aug 14, 2026, 11:40Liz Devlin: When HHT Affects More Than What We Can See
-
Aug 14, 2026, 11:29Archil Jaliashvili: Can Italy Reduce Its Dependence on Imported Plasma